• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TeraDiscoveries, Egenix partner for cancer, autism drugs

TeraDiscoveries, Egenix partner for cancer, autism drugs

February 26, 2014
CenterWatch Staff

TeraDiscoveries has formed a strategic partnership with Egenix, a privately held New York-based biotechnology firm. The two companies are working together to design new drugs to treat cancer and autism.  

TeraDiscoveries will use its Inverse Design software platform to design new drug molecules to effectively help Egenix accelerate its drug discovery and development process. Egenix is providing funding and target data that TeraDiscoveries will apply to identify and optimize inhibitors for certain cancer indications and autism. Egenix will develop the drugs through phase II, while TeraDiscoveries retains a minority stake in the two drugs.

Inverse Design runs computational models to quickly scan a vast chemical space to find the strongest inhibitors of a specific biological target, ones that also have good druggable properties and are predicted to have low toxic side effects. Inverse Design also has filters for many important drug properties including toxic side-effect risk assessment, off-target effects assessment, synthesizability, solubility and freedom to operate assessment. Specialized filtering can assess if a molecule crosses the blood-brain barrier.

Companies can use Inverse Design as a service and run it via the Windows Azure cloud or a private cloud to design, discover or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also partners and licenses assets in its pipeline which include compounds for many targets including Jak2, Jak3, hdac8, Aurora A, 11b-HSD1, hsp90, MAPK10, pfDHFR-Ts, ABL1, ABL3, ROCK1, TYK2 and c-Kit.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing